BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models

• Most Recent Release (2026-04-21): BriaCell presented preclinical data for its Bria-OTS+ platform at the AACR Annual Meeting. The data shows activation of innate and adaptive immune systems in breast and prostate cancer models.
  • Clinical Roadmap: Plans to advance Bria-OTS+ into clinical trials for metastatic breast and prostate cancer later in 2026. Lung cancer and melanoma planned for 2027.
  • Mechanism: Designed to activate T cells and NK cells, with antigen-presenting cells priming tumor-specific T cells.
• Previous Release (2026-04-20): Presented positive Phase 3 Quality of Life (QOL) data for Bria-IMT plus immune checkpoint inhibitor (CPI).
  • Findings: Global health status remained stable; favorable safety profile in heavily pretreated patients.
  • Biomarkers: Identified mitotic circulating tumor cells (CTCs) and PD-L1 expression in macrophage fusion cells as prognostic markers.
• Historical Context (Jan 2026): Closed $30 million public offering at $5.59 per unit, issuing warrants exercisable at $6.93.
  • Impact: Significant dilution event; stock price dropped from ~$15 to ~$6 following the financing.
• Historical Context (Feb 2026): Data Safety Monitoring Board (DSMB) gave fifth consecutive positive safety recommendation for Phase 3 Bria-ABC study.
  • Asset Purchase: Completed transaction acquiring exclusive license to soluble CD80 (sCD80) from BriaPro, increasing ownership stake in subsidiary to ~78%.

• Incremental Nature: The preclinical data for Bria-OTS+ is positive but represents a secondary pipeline asset. It does not alter the primary value driver, which remains the Phase 3 readout of Bria-IMT expected in H1 2026.
• Market Expectations: Preclinical updates were anticipated following previous presentations at SITC (Nov 2025) and AACR (April 2026). The market has already priced in the Phase 3 timeline; this news confirms progress on a later-stage asset without immediate revenue implications.
• Dilution Overhang: The $30 million financing in January 2026 introduced significant share dilution and warrant pressure (exercise price $6.93). Current trading levels (~$5.49) are below the warrant strike, limiting immediate upside from warrant exercise but capping near-term valuation growth until clinical catalysts materialize.
• Risk of Translation: Moving from preclinical models to human trials carries inherent risk. While safety is favorable in Phase 3 (Bria-IMT), Bria-OTS+ has not yet entered the clinic, making this news speculative relative to the core asset.

• Company: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on cancer immunotherapy.
• Flagship Project: Bria-IMT (Allogenic Whole Cell-Based Cancer Vaccine).
  • Indication: Metastatic Breast Cancer (MBC).
  • Combination Therapy: Used in conjunction with an immune checkpoint inhibitor (CPI).
  • Status: Pivotal Phase 3 trial (Bria-ABC) ongoing. FDA Fast Track designation granted.
• Secondary Platform: Bria-OTS+ (Next-generation genetically engineered whole-cell cancer immunotherapy).
  • Indications: Breast, Prostate, Lung, Melanoma.
  • Status: Preclinical data presented; clinical trials planned for late 2026.
• Mechanism of Action: Designed to activate innate and adaptive immune systems (CD4+, CD8+ T cells, NK cells) to overcome tumor resistance mechanisms.